Forget Moderna Stock, This is a Much Better Buy

Investors flocked to Moderna (NASDAQ: MRNA) stock in the early days of the pandemic for one big reason: The company sold one of the world's most-needed products, a coronavirus vaccine. The vaccine brought in billions of dollars of revenue, and with this first product, Moderna went from a clinical-stage biotech to a highly profitable commercial-stage company in a matter of months.Though Moderna stock soared back then, in more recent times, the stock has stumbled. The company has seen vaccine sales decline, and its second big product -- its respiratory syncytial virus (RSV) vaccine -- hasn't performed as well as expected when it comes to delivering growth. Still, Moderna has made progress on cost cuts and has refocused its pipeline on several promising programs. And investors may be taking notice. The stock has climbed more than 30% over the past month.But, if you're looking to invest in a surefire biotech winner, forget Moderna stock. The following player is a much better buy...Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool